Trial Profile

A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non Hodgkin's Lymphoma (NHL)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JBH 492 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

31 Oct 2024 Status changed from active, no longer recruiting to discontinued.
29 Sep 2024 This trial has been Completed in Germany, according to European Clinical Trials Database record.
27 Sep 2024 This trial has been Discontinued in Finland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com